Loading clinical trials...
Loading clinical trials...
This study will investigate the individual safety and efficacy of two dual PI3K/mTOR inhibitors in patients with recurrent endometrial cancer.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Pfizer
NCT07046923 · Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, and more
NCT05129969 · Ovarian Cancer, Endometrial Cancer, and more
NCT06751329 · Ovarian Neoplasms, Prostatic Neoplasms, and more
NCT05770102 · Malignancy, Malignant Neoplasm, and more
NCT07114653 · Endometrial Neoplasms
University of Alabama at Birmingham
Birmingham, Alabama
University of Alabama at Birmingham, IDS Pharmacy
Birmingham, Alabama
University of Alabama at Birmingham
Birmingham, Alabama
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions